Supernus Pharmaceuticals Files 8-K

TL;DR

Supernus Pharma filed an 8-K, mostly just financial docs, no big news.

AI Summary

On May 9, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating no major new events or material changes requiring immediate disclosure beyond routine reporting. The company is based in Rockville, MD, and operates within the pharmaceutical preparations industry.

Why It Matters

This 8-K filing serves as a routine update, primarily detailing financial statements and exhibits, without announcing significant new events or changes for Supernus Pharmaceuticals.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, indicating no new material events or risks.

Key Players & Entities

• Supernus Pharmaceuticals, Inc. (company) — Registrant
• May 9, 2024 (date) — Date of earliest event reported
• Rockville, MD (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto

Filing Documents

• supn-20240509.htm (8-K) — 28KB
• ex99105-09x2024.htm (EX-99.1) — 12KB
• image_0.jpg (GRAPHIC) — 5KB
• 0001356576-24-000031.txt ( ) — 173KB
• supn-20240509.xsd (EX-101.SCH) — 2KB
• supn-20240509_lab.xml (EX-101.LAB) — 21KB
• supn-20240509_pre.xml (EX-101.PRE) — 12KB
• supn-20240509_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On May 9, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release announcing it will host a webcast and conference call at 4:30 p.m. Eastern Time on Thursday, May 23, 2024, to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. A live webcast with presentation slides will be available at www.supernus.com. The webcast and presentation slides will be archived on the Company's website for 60 days following the live call. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. This Current Report on Form 8-K contains "forward-looking statements" that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as "believe," "expect," "intend," "may," "will," "should," or "anticipate" or similar terminology. All statements other than statements of historical facts included in this Current Report on Form 8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except for Supernus' ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition to the risks and uncertainties of ordinary business operations and conditions in the general economy and the markets in which Supernus competes, the forward-looking statements of Supernus contained in this Current Report on Form 8-K are also subject to various risks and uncertainties, including those set forth in Item 1A, "Risk Factors," in Supernus' Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other risk factors se

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 — Press Release Dated May 9, 2024 furnished as an Exhibit pursuant to Item 8.01 hereof. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: May 9, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3